Loading
Akebia Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Mar 2026.
Akebia Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Akebia Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Akebia Therapeutics, Inc. logged 22 filings by 13 insiders.
The record shows 1 purchase on the open market worth €75k, made by 1 insider, against 7 sales worth €246k by 6 insiders. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €75k, the purchase published on 5 March 2026 by Butler John P. is the largest of the period. Among those who bought: 1 chief executive.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 22 filings, this issuer sits above that mark. Our records for Akebia Therapeutics, Inc. go back to 2016, with 1 purchase and 47 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 236.2 m USD and net income of -5.3 m USD.
The clock since the last published purchase (5 March 2026) now reads 227 days. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
124
Thresholds
n/a
Buy Volume
€74,566
1 ops. · all time
Sell Volume
€1M
47 ops. · all time
Who traded when
BuySaleErik Ostrowski3 sales
John P. Butler1 buy2 sales
Richard C. Malabre2 sales
Steven Keith Burke2 sales
Carolyn M. Rucci1 sale
Nicholas Grund1 sale
Since the insiders bought
- -23.6%Entry US$1.27 · Close at T+90 US$0.97
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,393 of 24,148 companies
48.4
score / 100
Value57
Quality40
FCF yld32%
Earn yld-2.9%
EV/EBITDA10.9x
ROE-109%
Gross mgn83%
Net mgn-2.3%
Debt/EBITDA2.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.77
Analyst consensus
6 analysts1.50/5
US$1.00Target US$3.92(+409%)US$6.00
Income statement
RevenueUS$236.2M
Gross profitUS$196.7M83% margin
EBITDAUS$21.7M9% margin
Net income-US$5.3M-13.5% margin
Valuation
PER (forward)-2.1x
P/Book8.4x
Beta0.18
Balance sheet & cash
Market capUS$213.4M
Total debtUS$51.8M
Free Cash FlowUS$59.9M
Debt / Equity796%
Profitability & ownership
ROE-109.4%
ROA-1.1%
% insiders2.0%
% institutions40.8%
Last declaration on 10 August 2026
Declarations124 total
350,000 shares@ US$0.630.084% mcap30.2% of flowCommon StockSEC:0001591467-26-000004:0
56,019 sharesCommon StockSEC:0001762507-26-000004:0
56,019 shares@ US$1.11070.024% mcap24.3% of flowCommon StockSEC144:0001517022-26-000044
35,700 sharesCommon StockSEC:0001248144-26-000001:0
35,700 sharesCommon StockSEC:0001204946-26-000001:0
35,700 sharesCommon StockSEC:0001244159-26-000001:0
35,700 sharesCommon StockSEC:0001609480-26-000003:0
35,700 sharesCommon StockSEC:0001808317-26-000001:0
35,700 sharesCommon StockSEC:0001890219-26-000001:0
69,270 shares@ US$1.2511.8% of flowCommon StockSEC:0001591467-26-000003:0
Canonical exit: 2 Jun 2026 (T+90)
16,846 shares@ US$1.39100.0% of flowCommon StockSEC:0002107264-26-000006:0
36,142 shares@ US$1.3940.1% of flowCommon StockSEC:0002007730-26-000002:0
34,951 shares@ US$1.3918.3% of flowCommon StockSEC:0001762507-26-000002:0
53,585 shares@ US$1.39100.0% of flowCommon StockSEC:0001661887-26-000002:0
21,582 shares@ US$1.3914.1% of flowCommon StockSEC:0001619834-26-000002:0
46,660 shares@ US$1.398.7% of flowCommon StockSEC:0001591467-26-000002:0
190,000 shares0Common StockSEC:0002107264-26-000005:0
79,000 shares0Common StockSEC:0002007730-26-000001:0
204,000 shares0Common StockSEC:0001762507-26-000001:0
204,000 shares0Common StockSEC:0001661887-26-000001:0
204,000 shares0Common StockSEC:0001619834-26-000001:0
743,000 shares0Common StockSEC:0001591467-26-000001:0
41,314 shares@ US$3.6757.4% of flowCommon StockSEC:0001562180-25-005201:0
35,700 shares0Common StockSEC:0001562180-25-004723:0
35,700 shares0Common StockSEC:0001562180-25-004722:0
25 of 124 declarations
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States, with a focused franchise in kidney disease and kidney-disease-related conditions. Founded in 2007, the company has developed as an integrated biotech platform combining clinical development, regulatory work, commercialization, and market access execution. Its headquarters are in Cambridge, Massachusetts, placing it in one of the most established life-science clusters in the country.
Akebia’s business model is centered on two main pillars: commercial products and pipeline development. Its lead commercial asset is Vafseo (vadadustat), an oral therapy for certain adults with anemia due to chronic kidney disease, which has become the company’s key growth driver as it continues to expand in the U.S. market. Akebia also markets Auryxia (ferric citrate), a renal product used to treat hyperphosphatemia in patients with chronic kidney disease on dialysis and iron deficiency anemia in certain non-dialysis CKD patients. These marketed products give Akebia a revenue base, but they also create concentration risk, especially given generic competition and reimbursement sensitivity.
Read moreShow less
From a competitive standpoint, Akebia is a specialist rather than a broad nephrology leader. Its position is shaped by deep therapeutic expertise in kidney disease, a commercial infrastructure built around renal prescribers, and a pipeline intended to extend the company’s relevance beyond the first wave of launches. In this segment, differentiation depends on clinical utility, safety, dosing convenience, and access to the appropriate patient population. Akebia’s strategy is therefore less about scale and more about targeted execution in a high-need, medically complex market.
Recent developments underscore that the company is still in a transition phase. In early 2026, Akebia reported full-year 2025 results and commercial highlights around Vafseo’s launch, while also discussing a broader kidney-disease pipeline. In April 2026, the company held a virtual R&D Day focused on its kidney disease programs. Management also indicated that Auryxia revenue is expected to face pressure from expanding generic competition in 2026. For investors, Akebia represents a small-cap U.S. biotech with a commercial plus pipeline profile, where the investment case hinges on Vafseo uptake, Auryxia resilience, and the pipeline’s ability to create additional growth options.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
